|
1
|
Bird JM, Owen RG, D’Sa S, et al:
Guidelines for the diagnosis and management of multiple myeloma
2011. Br J Haematol. 154:32–75. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singhal S, Mehta J, Desikan R, et al:
Antitumor activity of thalidomide in refractory multiple myeloma. N
Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Richardson PG, Barlogie B, Berenson J, et
al: A phase 2 study of bortezomib in relapsed, refractory myeloma.
N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rajkumar SV, Hayman SR, Lacy MQ, et al:
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex)
for newly diagnosed myeloma. Blood. 106:4050–4053. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Richardson PG, Sonneveld P, Schuster MW,
et al: Bortezomib or high-dose dexamethasone for relapsed multiple
myeloma. N Engl J Med. 352:2487–2498. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Richardson PG, Blood E, Mitsiades CS, et
al: A randomized phase 2 study of lenalidomide therapy for patients
with relapsed or relapsed and refractory multiple myeloma. Blood.
108:3458–3464. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kelekar A and Thompson CB: Bcl-2-family
proteins: the role of the BH3 domain in apoptosis. Trends Cell
Biol. 8:324–330. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pulley H and Mohammad R: Small-molecule
inhibitors of Bcl-2 protein. Drugs Future. 29:369–381. 2004.
View Article : Google Scholar
|
|
9
|
Reed JC: Bcl-2 family proteins. Oncogene.
17:3225–3236. 1998. View Article : Google Scholar
|
|
10
|
Adams JM and Cory S: The Bcl-2 protein
family: arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Q and Gazitt Y: Potentiation of
dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2
antisense oligodeoxynucleotides in drug-resistant multiple myeloma
cells. Blood. 101:4105–4114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang JS, Hsu YL, Kuo PL, Chiang LC and
Lin CC: Upregulation of Fas/Fas ligand-mediated apoptosis by
gossypol in an immortalized human alveolar lung cancer cell line.
Clin Exp Pharmacol Physiol. 31:716–722. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tuszynski GP and Cossu G: Differential
cytotoxic effect of gossypol on human melanoma, colon carcinoma,
and other tissue culture cell lines. Cancer Res. 44:768–771.
1984.PubMed/NCBI
|
|
14
|
Zhang M, Liu H, Guo R, et al: Molecular
mechanism of gossypol-induced cell growth inhibition and cell death
of HT-29 human colon carcinoma cells. Biochem Pharmacol. 66:93–103.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jaroszewski JW, Kaplan O and Cohen JS:
Action of gossypol and rhodamine 123 on wild type and
multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear
magnetic resonance and toxicity studies. Cancer Res. 50:6936–6943.
1990.PubMed/NCBI
|
|
16
|
Le Blanc M, Russo J, Kudelka AP and Smith
JA: An in vitro study of inhibitory activity of gossypol, a
cottonseed extract, in human carcinoma cell lines. Pharmacol Res.
46:551–555. 2002.PubMed/NCBI
|
|
17
|
Stein RC, Joseph AE, Matlin SA, Cunningham
DC, et al: A preliminary clinical study of gossypol in advanced
human cancer. Cancer Chemother Pharmacol. 30:480–482. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Enyedy IJ, Ling Y, Nacro K, et al:
Discovery of small-molecule inhibitors of Bcl-2 through
structure-based computer screening. J Med Chem. 44:4314–4324. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kitada S, Leone M, Sareth S, et al:
Discovery, characterization and structure-activity relationships
studies of proapoptotic polyphenols targeting B-cell
lymphocyte/leukemia-2 proteins. J Med Chem. 46:4259–4264. 2003.
View Article : Google Scholar
|
|
20
|
Yunis JJ, Frizzera G, Oken MM, et al:
Multiple recurrent genomic defects in follicular lymphoma, a
possible model for cancer. N Engl J Med. 316:79–84. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pettersson M, Jernberg-Wiklund H, Larsson
LG, et al: Expression of the bcl-2 gene in human multiple myeloma
cell lines and normal plasma cells. Blood. 79:495–502.
1992.PubMed/NCBI
|
|
22
|
Graninger WB, Seto M, Boutain B, Goldman P
and Korsmeyer SJ: Expression of bcl-2 and bcl-2-Ig fusion
transcripts in normal and neoplastic cells. J Clin Invest.
80:1512–1515. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jernberg H, Zech L and Nilsson K:
Cytogenetic studies on human myeloma cell lines. Int J Cancer.
40:811–817. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peeters SD, Hovenga S, Rosati S and
Vellenga E: Bcl-xl expression in multiple myeloma. Med Oncol.
22:183–190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Linden M, Kirchhof N, Carlson C and Van
Ness B: Targeted overexpression of Bcl-xl in B-lymphoid cells
results in lymphoproliferative disease and plasma cell
malignancies. Blood. 103:2779–2786. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu L, Yang D, Wang S, et al: (−)-Gossypol
enhances response to radiation therapy and results in tumor
regression of human prostate cancer. Mol Cancer Ther. 4:197–205.
2005.
|
|
27
|
Jiang J, Sugimoto Y, Liu S, et al: The
inhibitory effects of gossypol on human prostate cancer cells-PC3
are associated with transforming growth factor beta1 (TGFbeta1)
signal transduction pathway. Anticancer Res. 24:91–100.
2004.PubMed/NCBI
|
|
28
|
Band V, Hoffer AP, Band H, et al:
Antiproliferative effect of gossypol and its optical isomers on
human reproductive cancer cell lines. Gynecol Oncol. 32:273–277.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Coyle T, Levante S, Shetler M and Winfield
J: In vitro and in vivo cytotoxicity of gossypol against central
nervous system tumor cell lines. J Neurooncol. 19:25–35. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benz CC, Keniry MA, Ford JM, et al:
Biochemical correlates of the antitumor and antimitochondrial
properties of gossypol enantiomers. Mol Pharmacol. 37:840–847.
1990.PubMed/NCBI
|
|
31
|
Shelley MD, Hartley L, Groundwater PW and
Fish RG: Structure-activity studies on gossypol in tumor cell
lines. Anticancer Drugs. 11:209–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jarvis WD, Turner AJ, Povirk LF, Traylor
RS and Grant S: Induction of apoptotic DNA fragmentation and cell
death in HL-60 human promyelocytic leukaemia cells by
pharmacological inhibitors of protein kinase C. Cancer Res.
54:1707–1714. 1994.PubMed/NCBI
|
|
33
|
Blackstaffe L, Shelley MD and Fish RG:
Cytotoxicity of gossypol enantiomers and its quinone metabolite
gossypolone in melanoma cell lines. Melanoma Res. 7:364–372. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mohammad RM, Wang S, Aboukameel A, et al:
Preclinical studies of a nonpeptidic small-molecule inhibitor of
Bcl-2 and Bcl-X(L) [(−)-gossypol] against diffuse large cell
lymphoma. Mol Cancer Ther. 4:13–21. 2005.
|
|
35
|
Ergun MA, Konac E, Erbas D and Ekmekci A:
Apoptosis and nitric oxide release induced by thalidomide, gossypol
and dexamethasone in cultured human chronic myelogenous leukemic
K-562 cells. Cell Biol Int. 28:237–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hou DX, Uto T, Tong X, et al: Involvement
of reactive oxygen species-independent mitochondrial pathway in
gossypol-induced apoptosis. Arch Biochem Biophys. 428:179–187.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bushunow P, Reidenberg MM, Wasenko J, et
al: Gossypol treatment of recurrent adult malignant gliomas. J
Neurooncol. 43:79–86. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Flack MR, Pyle RG, Mullen NM, Lorenzo B,
et al: Oral gossypol in the treatment of metastatic adrenal cancer.
J Clin Endocrinol Metab. 76:1019–1024. 1993.PubMed/NCBI
|
|
39
|
Van Poznak C, Seidman AD, Reidenberg MM,
et al: Oral gossypol in the treatment of patients with refractory
metastatic breast cancer: a phase I/II clinical trial. Breast
Cancer Res Treat. 66:239–248. 2001.PubMed/NCBI
|
|
40
|
Oliver CL, Miranda MB, Shangary S, et al:
(−)-Gossypol acts directly on the mitochondria to overcome Bcl-2-
and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther.
4:23–31. 2005.
|
|
41
|
Oliver CL, Bauer JA, Wolter KG, et al: In
vitro effects of the BH3 mimetic, (−)-gossypol, on head and neck
squamous cell carcinoma cells. Clin Cancer Res. 10:7757–7763.
2004.
|
